View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
August 5, 2010

EnteroMedics to Trial Hunger Blocking Device

EnteroMedics is planning a trial of its VBLOC vagal blocking therapy, after the device received a conditional investigational device exemption from the US Food and Drug Administration. The ReCharge trial will evaluate the safety and efficacy of VBLOC therapy as an obesity treatment.

By cms admin

EnteroMedics is planning a trial of its VBLOC vagal blocking therapy, after the device received a conditional investigational device exemption from the US Food and Drug Administration.

The ReCharge trial will evaluate the safety and efficacy of VBLOC therapy as an obesity treatment.

The VBLOC therapy involves implanting leads laparoscopically and delivering high-frequency, low-energy impulses to block the vagus nerve, which affects perceptions of hunger and fullness.

The trial will be a randomised and multi-centre controlled trial, and will involve 234 morbidly obese subjects.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management